Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NM 004

Drug Profile

NM 004

Alternative Names: 5-ASA+4-APAA; Apaza™; INN-108; NAA-004; NM-004

Latest Information Update: 23 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon
  • Developer 9 Meters Biopharma
  • Class Anti-inflammatories; Nitrogen compounds; Phenylacetates; Radioprotectives; Salicylic acids; Small molecules
  • Mechanism of Action Immunomodulators; Interleukin 2 stimulants; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Radiation injuries; Ulcerative colitis

Most Recent Events

  • 23 Mar 2023 Discontinued - Phase-I for Ulcerative colitis (In adolescents, In children, In the elderly, In infants, In neonates, In adults) in USA (PO)
  • 22 Mar 2023 Discontinued - Phase-I for Ulcerative colitis (In adults) in USA (PO)
  • 19 Jul 2022 Discontinued - Phase-I for Inflammatory bowel diseases in USA (PO) (9 Meters Biopharma pipeline, July 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top